US2011003853A1PendingUtilityA1
Metalloproteinase Inhibitors
Est. expiryMar 15, 2021(expired)· nominal 20-yr term from priority
A61P 37/08A61P 43/00A61P 3/10A61P 7/00A61P 35/00A61P 9/10A61P 9/04A61P 35/04A61P 9/00A61P 7/02A61P 25/28A61P 29/00A61P 25/00A61P 27/02A61P 25/02A61P 17/00A61P 19/10A61P 19/04C07D 233/76C07D 471/04A61P 11/00A61P 17/04C07D 409/14A61P 1/16C07D 417/14C07D 403/04A61P 1/04C07D 405/14A61P 13/12A61P 17/02A61P 19/00A61P 1/00C07D 405/12A61P 11/06A61P 19/06C07D 403/06A61P 19/02A61P 11/02A61P 17/06A61P 19/08A61P 1/02C07D 401/14C07D 401/12C07D 403/12A61P 15/00C07D 233/78
55
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Compounds of the formula (I) wherein z is SO 2 or SO, useful as metalloproteinase inhibitors, especially as inhibitors of MMP12.
Claims
exact text as granted — not AI-modified1 - 16 . (canceled)
17 . (5S)-5-[({4-[(5-chloropyridin-2-yl)oxy]piperidin-1-yl}sulfonyl)methyl]-5-methylimidazolidine-2,4-dione or a pharmaceutically acceptable salt thereof or an in vivo hydrolysable ester thereof.
18 . (5S)-5-[{4-[(5-chloropyridin-2-yl)oxy]piperidin-1-yl}sulfonyl)methyl]-5-methylimidazolidine-2,4-dione or a pharmaceutically acceptable salt thereof.
19 . (5S)-5-[({4-[(5-chloropyridin-2-yl)oxy]piperidin-1-yl}sulfonyl)methyl]-5-methylimidazolidine-2,4-dione.
20 . (5S)-5-[({4-[(5-chloropyridin-2-yl)oxy]piperidin-1-yl}sulfonyl)methyl]-5-methylimidazolidine-2,4-dione in the form of a pharmaceutically acceptable salt.
21 . A pharmaceutical composition which comprises a compound or a pharmaceutically acceptable salt thereof or an in vivo hydrolysable ester thereof, as claimed in claim 17 , and a pharmaceutically acceptable carrier.
22 . A pharmaceutical composition which comprises a compound or a pharmaceutically acceptable salt thereof, as claimed in claim 18 , and a pharmaceutically acceptable carrier.
23 . A pharmaceutical composition which comprises a compound as claimed in claim 19 and a pharmaceutically acceptable carrier.
24 . A pharmaceutical composition which comprises a pharmaceutically acceptable salt as claimed in claim 20 , and a pharmaceutically acceptable carrier.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.